Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD7789

Bispecific antibody · Immune activation, directed at PD-1 (PDCD1) and TIM-3 (HAVCR2) · developed by ASTRAZENECA

Phase 1 Most advanced trial
AZN Developer

What is AZD7789?

AZD7789 (sabestomig) is a bispecific antibody that binds both PD-1 and TIM-3, two inhibitory immune checkpoint receptors co-expressed on tumor-antigen-specific T cells. By blocking these receptors' interactions with their ligands, it aims to relieve T-cell inhibition and enhance T-cell-mediated tumor cell killing. It is being studied in advanced or metastatic non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
sabestomig
Drug type
Bispecific antibody
Targets
PD-1 (PDCD1), TIM-3 (HAVCR2)
Mechanism
Immune activation, directed at PD-1 (PDCD1) and TIM-3 (HAVCR2)
Pathways
T-cell activation, PD-1/PD-L1 signaling, TIM-3 ligand interaction
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced or Metastatic NSCLC

Other drugs acting on PDCD1 / HAVCR2

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD7789

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.